US5238965A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods of using lysophosphatidic acids for regulating skin wrinkles
Assignee: Procter and Gamble Co
•
Filing: 1991-05-31
•
Granted: 1993-08-24
•
Expires: 2011-05-31
Abstract
Abstract The subject invention relates to methods for regulating wrinkles in mammalian skin comprising topical application of a lysophosphatidic acid compound having the structure: <IMAGE> or a cyclic derivative thereof having the structure: <IMAGE> or a pharmaceutically acceptable salt thereof, wherein -R is unsubstituted or substituted, saturated or unsaturated, straight or branched chain alkyl having from 12 to about 23 carbon atoms; each -X- is independently -O- or -S-; and -Y- is -O- or -CH2-.
Inventors
- 👤 Gary A. Piazza
- 👤 Adam W. Mazur
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 15:02
CPC Classifications
A; A61; A61Q; A61Q19/00; A61Q19/08; A61K; A61K31/00; A61K31/66; A61K31/665; A61K8/00; A61K8/18; A61K8/30; A61K8/55; A61K8/553; A61Q17/00; A61Q17/04; Y; Y10; Y10S; Y10S424/00; Y10S424/05
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
109 words
A method of preventing, retarding, arresting or reversing the process of wrinkle formation in mammalian skin comprising topically applying to the skin of a mammal a composition comprising a safe and effective amount of a lysophosphatidic acid compound having the structure: ##STR8## or a cyclic derivative thereof having the structure: ##STR9## or a pharmaceutically acceptable salt thereof, wherein --R is unsubstituted or substituted with a substituent selected from the group consisting of halogen, hydroxy, phenyl, amino and acylamino, saturated or unsaturated, straight or branched chain alkyl having from 12 to about 23 carbon atoms; each --X-- is independently --O-- or --S--; and --Y-- is --O-- or --CH 2 --.
Claim 2
Independent Claim
109 words
A method of preventing, retarding, arresting or reversing the process of wrinkle formation in mammalian skin comprising topically applying to the skin of a mammal a composition comprising a safe and effective amount of a lysophosphatidic acid compound having the structure: ##STR8## or a cyclic derivative thereof having the structure: ##STR9## or a pharmaceutically acceptable salt thereof, wherein --R is unsubstituted or substituted with a substituent selected from the group consisting of halogen, hydroxy, phenyl, amino and acylamino, saturated or unsaturated, straight or branched chain alkyl having from 12 to about 23 carbon atoms; each --X-- is independently --O-- or --S--; and --Y-- is --O-- or --CH 2 --.
Claim 3
Dependent Claim
15 words
The method of claim 1 wherein --R is unsubstituted or substituted with hydroxy or halogen.
Claim 4
Dependent Claim
8 words
The method of claim 2 wherein --X-- --O--.
Claim 5
Dependent Claim
12 words
The method of claim 3 wherein the compound has the structure. ##STR10##
Claim 6
Dependent Claim
9 words
The method of claim 4 wherein --Y-- is --O--.
Claim 7
Dependent Claim
9 words
The method of claim 5 wherein --R is unsubstituted.
Claim 8
Dependent Claim
18 words
The method of claim 6 wherein --R is straight-chain and is saturated or unsaturated with one double bond.
Claim 9
Dependent Claim
15 words
The method of claim 7 wherein --R has from bout 13 to 17 carbon atoms.
Claim 10
Dependent Claim
18 words
The method of claim 8 wherein RC(O)O-- is selected from the group consisting of oleyl, palmityl and myristyl.
Claim 11
Dependent Claim
9 words
The method of claim 9 wherein RC(O)O-- is myristyl.
Claim 12
Dependent Claim
30 words
The method of claim 1 wherein the amount of the lysophosphatidic acid compound applied to the skin is from about 0.01 mg to about 1 mg per cm 2 skin.
Claim 13
Dependent Claim
30 words
The method of claim 6 wherein the amount of the lysophosphatidic acid compound applied to the skin is from about 0.01 mg to about 1 mg per cm 2 skin.
Claim 14
Dependent Claim
30 words
The method of claim 8 wherein the amount of the lysophosphatidic acid compound applied to the skin is from about 0.01 mg to about 1 mg per cm 2 skin.
Claim 15
Dependent Claim
30 words
The method of claim 9 wherein the amount of the lysophosphatidic acid compound applied to the skin is from about 0.01 mg to about 1 mg per cm 2 skin.
Claim 16
Dependent Claim
143 words
A composition for topical application for preventing, retarding, arresting or reversing the process of wrinkle formation in mammalian skin comprising: (a) a safe and effective amount of a lysophosphatidic acid compound having the structure: ##STR11## or a cyclic derivative thereof having the structure: ##STR12## or a pharmaceutically acceptable salt thereof, wherein --R is unsubstituted or substituted with a substituent selected from the group consisting of halogen, hydroxy, phenyl, amino and acylamino, saturated or unsaturated, straight or branched chain alkyl having from 12 to about 23 carbon atoms; each --X-- is independently --O-- or --S--; and --Y-- is --O-- or --CH 2 --. (b) a safe and effective amount of a chelating agent capable of forming a complex with a metal ion so that the ion cannot participate in or catalyze chemical reactions; and (c) a safe and effective amount of a topical carrier.
Claim 17
Dependent Claim
143 words
A composition for topical application for preventing, retarding, arresting or reversing the process of wrinkle formation in mammalian skin comprising: (a) a safe and effective amount of a lysophosphatidic acid compound having the structure: ##STR11## or a cyclic derivative thereof having the structure: ##STR12## or a pharmaceutically acceptable salt thereof, wherein --R is unsubstituted or substituted with a substituent selected from the group consisting of halogen, hydroxy, phenyl, amino and acylamino, saturated or unsaturated, straight or branched chain alkyl having from 12 to about 23 carbon atoms; each --X-- is independently --O-- or --S--; and --Y-- is --O-- or --CH 2 --. (b) a safe and effective amount of a chelating agent capable of forming a complex with a metal ion so that the ion cannot participate in or catalyze chemical reactions; and (c) a safe and effective amount of a topical carrier.
Claim 18
Dependent Claim
33 words
The composition of claim 15 wherein the compound has the structure: ##STR13## wherein --R has from 13 to 17 carbon atoms, is straight-chain, is unsubstituted, and is saturated or has one double bond.
References Cited (Backward Citations)
US4104403A
Cited
JPH01174355A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-08-23 | 1997-02-22 | 1997-08-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-08-23 | 2001-02-22 | 2001-08-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-08-23 | 2005-02-22 | 2005-08-24 | $7700.00 | Window Closed / Lapsed |